Anti-ZnT8 Antibody (mAb43)
Based on 1 Customer Validation
Anti-ZnT8 Antibody (mAb43) is a monoclonal antibody targeting the zinc transporter ZnT8, with islet-specific biodistribution characteristics. Anti-ZnT8 Antibody (mAb43) binds to extracellular ZnT8 on the surface of pancreatic β-cells and masks its insulin-co-localizing sites to block autoimmune recognition. Anti-ZnT8 Antibody (mAb43) also promotes an increase in the proportion of regulatory T cells and inhibits B cell antigen presentation, thereby effectively blocking the T cell-mediated cascade of β-cell destruction. Anti-ZnT8 Antibody (mAb43) eliminates insulitis, preserves β-cell mass and induces seroconversion of autoantibodies, without directly altering the insulin secretion function or content of β-cells. Anti-ZnT8 Antibody (mAb43) can be used for research related to type 1 diabetes.
For research use only. We do not sell to patients.
- Purity: 99.40%
- Molecular Weight:145.79 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Mouse IgG2a kappa
Recommend Isotype Controls
Species Reactivity
Human
In Vivo
Anti-ZnT8 Antibody (mAb43) (5 mg/kg; i.v.; weekly; up to 26 weeks) administered from 14 weeks of age provides prolonged protection against spontaneous type 1 diabetes in female NOD mice[1].
Anti-ZnT8 Antibody (mAb43) (5 mg/kg; i.v.; weekly; 11 weeks) has no detectable adverse effects on β-cell function, glucose homeostasis, or insulitis in male B6 db mice with obesity-induced type 2 diabetes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD/ShiLtJ (female, 10 weeks old at treatment initiation)[1]
-
Dosage:5 mg/kg
-
Administration:i.v.; weekly; up to 25 weeks
-
Result:Maintained euglycemia through 35 weeks of age in all 64 treated mice, with only one mouse experiencing a transient hyperglycemic episode that resolved to FBG <250 mg/dL.
Achieved 100% nondiabetic rate, compared to 0% of control mice.
Exhibited significantly higher β-cell mass than diabetic control mice at all ages.
Showed median insulitis severity between that of control mice with acute or progressive T1D onset at 20 weeks of age; extending treatment to 35 weeks resulted in significant clearance of destructive insulitis.
Achieved complete insulin autoantibody (IAA) negativity by 35 weeks of age.
Significantly increased the number of CD4+FoxP3+CD25+ regulatory T cells (Tregs) within pancreatic islets, with no significant changes in total CD4+ T cells.
Shifted islet-residing CD4+ T cells toward higher FoxP3 expression without altering immune cell subsets or phenotypes in pancreatic lymph nodes or spleens.
Gene ID
Accession
Q8IWU4
Target
SLC30A8/ZnT8
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145.79 kDa
-
Color Colorless to light yellow
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anti-ZnT8 Antibody (mAb43) Related Classifications
HY-P992159 Related Classifications
Powered by Bioz